# Trial to Evaluate the Efficacy and Safety of HCP1302

Study · id `cardio:ct-nct02587988` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02587988](<https://clinicaltrials.gov/study/NCT02587988>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02587988

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 232 participants.

## Technical summary

Registry record NCT02587988. Randomized; double masking; primary purpose treatment. Start 2014-09 (registry gives no type); primary completion 2015-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 232 participants (enrolled count; ClinicalTrials.gov record NCT02587988, source copy `cardio:ctgov-nct02587988-2016-11-01`, retrieved 2026-10-26)
- Start date: 2014-09 (registry gives no type) (ClinicalTrials.gov record NCT02587988, source copy `cardio:ctgov-nct02587988-2016-11-01`, retrieved 2026-10-26)
- Primary completion: 2015-05 (actual) (ClinicalTrials.gov record NCT02587988, source copy `cardio:ctgov-nct02587988-2016-11-01`, retrieved 2026-10-26)
- Completion: 2015-08 (actual) (ClinicalTrials.gov record NCT02587988, source copy `cardio:ctgov-nct02587988-2016-11-01`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02587988-2016-11-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Trial to Evaluate the Efficacy and Safety of HCP1302
- Condition: Erectile Dysfunction
- Condition: Hypertension
- Intervention (Drug): HCP1302
- Intervention (Drug): HGP0904
- Intervention (Drug): Placebo (for HCP1302)
- Intervention (Drug): Placebo (for HGP0904)
- Lead sponsor: Hanmi Pharmaceutical Company Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Hanmi Pharmaceutical Company Limited (`cardio:org-hanmi-pharmaceutical-company-limited`)

## Provenance

Content hash: 8e414a46e452c52e3ed78f74a5f3c7d6cba178d9835507a2b90d8625d0fe0f8b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
